The use of Il18r1 KO mice or anti-IL-18 treatment did not result in significant differences in tumor growth rate and survival among CTXpre-experienced groups (WT-CTXpre, WT-CTXpre + αIL-18, Il18r1 KO-CTXpre; Fig. 5j, k), which had low proportion of IL-18Rαhi T cells. This evidence concerns the gene IL18 and neoplasm.